News Releases

News and information from The Leukemia & Lymphoma Society

LLS Applauds Data From Phase 2 Study of Venetoclax for High-Risk CLL Patients

White Plains, N.Y. (August 19, 2015) – The Leukemia & Lymphoma Society (LLS) welcomes the news that an investigational therapy to treat patients with a high-risk subset of chronic lymphocytic leukemia (CLL) has shown very positive results in a Phase II clinical trial. There are more than 126,000 patients in the United States currently living with CLL, a typically slow-moving blood cancer that begins in the b...

Valor Biotherapeutics to Begin Phase 1 Clinical Study of Novel Lymphoma Therapy

The Leukemia & Lymphoma Society has partnered with Valor Biotherapeutics and committed $6 million to advance this therapy into a Phase 1 clinical study   The Leukemia & Lymphoma Society
Contact: Andrea Greif
Tel: (914) 821-8958
Cell: (914) 772-3027
andrea.greif@lls.org Valor Biotherapeutics/ImmunGene
Contact: Leah Grant
Tel: (206) 660-4003
leahgra...

RECORD-BREAKING 25TH YEAR FOR LLS’S MAN & WOMAN OF THE YEAR CAMPAIGN

Contact: Kristin Hoose
(914) 821-8973
kristin.hoose@lls.org -COMMUNITY LEADERS RAISED $32 MILLION TO HELP FIND CANCER CURES-  White Plains, NY (July 28, 2015) – They say “Everything’s bigger in Texas,” and “The city so nice they named it twice,” to describe Texas and New York, and two dynamic fundraisers in Texas and New York City proved them right by raising a combined total of a...

LLS Applauds House Approval of 21st Century Cures Act

Contact: Andrea Greif
(914) 821-8958 (p)
(914) 772-3027 (c)
andrea.greif@lls.org White Plains, N.Y. (July 10, 2015) – The Leukemia & Lymphoma Society (LLS) commends the U.S. House of Representatives for today’s overwhelming approval of the 21st Century Cures Act. This law, if enacted by the full Congress, will significantly speed access to new lifesaving therapies for blood cancer pati...

Kite Pharma and LLS Collaborate on CAR T-Cell Therapy for Lymphoma

Contact: Andrea Greif
(914) 821-8958 (p)
(914) 772-3027 (c)
andrea.greif@lls.org Santa Monica, Calif., and White Plains, NY: July 1, 2015 – Kite Pharma, Inc., KITE, +2.77% and The Leukemia & Lymphoma Society (LLS) announced today that they have entered into a partnership to enhance the development of Kite's lead product candidate, KTE-C19, for the treatment of patient...

LLS Applauds Data from Celator Study of CPX-351 for High-Risk AML Patients

Contact: Andrea Greif
(914) 821-8958 (p)
(914) 772-3027 (c)
andrea.greif@lls.org White Plains, N.Y. (June 24, 2015) – Interim data released today by Celator Pharmaceuticals regarding its study of CPX-351,  a special formulation of two standard chemotherapy drugs, to treat elderly patients with high-risk acute myeloid leukemia (AML), is a positive advance for patients with few options fo...

LLS Sorry to Learn of Maryland Governor’s Lymphoma Diagnosis

Contact: Andrea Greif
(914)821-8958 (p)
(914)772-3027 (c)
andrea.greif@lls.org White Plains, NY (June 22, 2015) – The Leukemia & Lymphoma Society (LLS) was sorry to learn this afternoon that Maryland Gov. Larry Hogan has been diagnosed with non-Hodgkin lymphoma (NHL). His diagnosis is B-cell NHL, which is a diverse group of blood cancers that develop in the lymphatic system. While it ...

Leukemias With ALK Mutations Identified, May Respond to ALK Inhibitors

This news release is being distributed by the Knight Cancer Institute at Oregon Health & Science University. The research is partially funded by The Leukemia & Lymphoma Society. Contact: Elisa Williams (OHSU)
(971) 344-5441
willieli@ohsu.edu
Philadelphia, PA (June 1, 2015) — Mutations in the ALK gene were identified in the tumors of two leukemia patients, and laboratory studies i...

Pages

Media Contact

Have media inquiries? Contact us between 9 a.m. and 5 p.m. ET, Monday through Friday: